Bioton (FRA:7U5) Moat Score: 0/10 (As of Jul. 08, 2026)


FRA:7U5 Bioton SA FRA:7U5
61 GF Score
Price €0.88
GF Value €1.05
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Bioton Moat Score?

Bioton has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Bioton has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Bioton might have No Moat - No discernible moat.

Bioton  (FRA:7U5) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Bioton Moat Score Related Terms

FRA:7U5
61GF Score
Bioton SA FRA:7U5
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Bioton (FRA:7U5) Overvalued in 2026?

Based on GuruFocus' analysis, Bioton stock appears to be undervalued. The current stock price of €0.88 is trading 16.6% below its estimated GF Value™ of €1.05. GuruFocus considers Bioton to be Modestly Undervalued.

Key valuation signals for FRA:7U5:

  • Moat Score: 0
  • GF Value™: €1.05 vs. price of €0.88 (16.6% below fair value)
  • GF Score™: 61/100 with 3 warning signs

No single metric tells the full story. See the FRA:7U5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bioton Business Description

Other Exchanges BIO:Poland
Address Ul. Starościńska 5, Warszawa, POL, 02-516
Bioton SA is a Poland based company engaged in the principal business activity of manufacturing medicines and pharmaceutical preparations and production of pharmaceutical substances. The products of the company include recombinant human insulin in pharmaceutical substance form and as preparations for injections; glimepiride, an oral hypoglycemic drug; and metformin, an oral hypoglycemic drug. Its products line focuses on diet supplements, products for particular nutritional uses and cosmetics dedicated to patients with certain health problems. The group operates in Poland and internationally, of which majority of the revenue is derived from Poland.
61GF Score

Get the complete analysis for FRA:7U5

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price
€1.05
GF Value